Completed OBSERVATIONAL NCT00922766

Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

Sponsor: Pfizer

Interventions Dalteparin

Updated 8 times since 2017 Last updated: Jan 19, 2012 Started: May 31, 2009 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00922766, this observational or N/A phase trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by Pfizer, it has been updated 8 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed
Sep 2025 — Jan 2026 [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Ambernath (E), India , Bangalore, India , Bikaner, India , Chennai, India , Hisar, India , Jaipur, India , Kolkata, India , Manglore, India , Mysore, India and 5 more locations